Work

Corrigendum to “The Totality of Evidence for SDZ-deno: A Biosimilar to Reference Denosumab” [Clin Ther. 2024;46:916-926]

Year: 2025

Type: erratum

Abstract: The authors regret that Figure 5 in the original publication contained an error in data presentation. The corrected version of Figure 5 is provided. This correction does not affect the overall findings, interpretation, or conclusions of the study.

Source: Clinical Therapeutics

DOI: 10.1016/j.clinthera.2025.07.019

Authors: Barbara Vogg, Johann Poetzl, Arnd Schwebig, Susmit Sekhar, Alan Kivitz, Natalia Krivtsova, Oliver Renner, Jean-Jacques Body, Richard Eastell

Institutions: Hexal (Germany), Altoona Center for Clinical Research, Université Libre de Bruxelles, Centre Hospitalier Universitaire Brugmann, University of Sheffield

Language: English

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,240

Funder: Hexal AG

OpenAlex ID: W4413258293

Cites:

Cited by:

Related to: 10